Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes

Therapeutic Drug Monitoring

Volumn 35, Issue 2, 2013, Pages 150-167

  Gotta, Verena ^a,b   Buclin, Thierry ^a   Csajka, Chantal ^a,b   Widmer, Nicolas ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

drug monitoring; meta analysis; oncology; simulation; tyrosine kinase inhibitors

Indexed keywords

2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; ALBUMIN; IMATINIB; OROSOMUCOID;

ANEMIA; AREA UNDER THE CURVE; BODY WEIGHT; CHRONIC MYELOID LEUKEMIA; DATA EXTRACTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG WITHDRAWAL; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; MEDLINE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; ONCOLOGY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RASH; REVIEW; SIDE EFFECT; SIMULATION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; HUMANS; NEOPLASMS; PIPERAZINES; POPULATION SURVEILLANCE; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84875144042     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318284ef11     Document Type: Review

References (80)

1. Teng JF, Mabasa VH, Ensom MH. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther Drug Monit. 2012; 34: 85-97.
2. Bouchet S, Royer B, Le GC, et al. Therapeutic drug monitoring of tyrosine-kinase inhibitors in the treatment of chronic myelogenous leukaemia: interests and limits. Therapie. 2010; 65: 213-218.
3. Cortes JE, Egorin MJ, Guilhot F, et al. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia. 2009; 23: 1537-1544.
4. Gao B, Yeap S, Clements A, et al. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol. 2012; 30: 4017-4025.
5. George S, Trent J. The role of imatinib plasma level testing in gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2011; 67: 45-50.
6. Mahon FX. Pharmacologic monitoring and determinants of intracytoplasmic drug levels. Best Pract Res Clin Haematol. 2009; 22: 381-386.
7. Patel S. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance. Cancer Treat Rev. 2012; 38: 467-472.
8. Takahashi N, Miura M. Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. Pharmacology. 2011; 87: 241-248.
9. von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for drug blood level testing? Cancer Treat Rev. 2011; 37: 291-299.
10. Buclin T, Widmer N, Biollaz J, et al. Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. Lancet Oncol. 2011; 12: 9-11.
11. Holford NH. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol. 1999; 48: 9-13.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188.
13. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27: 6041-6051.
14. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008; 112: 4437-4444.
15. Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008; 112: 837-845.
16. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23: 1054-1061.
17. Delbaldo C, Chatelut E, Re M, et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res. 2006; 12: 6073-6078.
18. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009; 27: 3141-3147.
19. Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol. 2005; 55: 379-386.
20. Menon-Andersen D, Mondick JT, Jayaraman B, et al. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol. 2009; 63: 229-238.
21. Petain A, Kattygnarath D, Azard J, et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res. 2008; 14: 7102-7109.
22. Schmidli H, Peng B, Riviere GJ, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol. 2005; 60: 35-44.
23. Widmer N, Decosterd LA, Csajka C, et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol. 2006; 62: 97-112.
24. Yamakawa Y, Hamada A, Nakashima R, et al. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011; 33: 244-250.
25. Widmer N, Decosterd LA, Csajka C, et al. Imatinib plasma levels: correlation with clinical benefit in GIST patients. Br J Cancer. 2010; 102: 1198-1199.
26. Widmer N, Decosterd LA, Leyvraz S, et al. Relationship of imatinibfree plasma levels and target genotype with efficacy and tolerability. Br J Cancer. 2008; 98: 1633-1640.
27. Gotta V, Widmer N, Montemurro M, et al. Therapeutic drug monitoring of imatinib: bayesian and alternative methods to predict trough levels. Clin Pharmacokinet. 2012; 51: 187-201.
28. Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol. 2004; 44: 158-162.
29. Awidi A, Ayed AO, Bsoul N, et al. Relationship of serum imatinib trough level and response in CML patients: Long term follow-up. Leuk Res. 2010; 34: 1573-1565.
30. Guilhot F, Hughes TP, Cortes J, et al. Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial. Haematologica. 2012; 97: 731-738.
31. Ishikawa Y, Kiyoi H, Watanabe K, et al. Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci. 2010; 101: 2186-2192.
32. Koren-Michowitz M, Volchek Y, Naparstek E, et al. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol. 2012; 30: 200-205.
33. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008; 111: 4022-4028.
34. Li-Wan-Po A, Farndon P, Craddock C, et al. Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example. Eur J Clin Pharmacol. 2010; 66: 369-374.
35. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28: 2381-2388.
36. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004; 22: 935-942.
37. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standarddose imatinib in chronic myeloid leukemia. Blood. 2007; 109: 3496-3499.
38. Sakai M, Miyazaki Y, Matsuo E, et al. Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group. Int J Hematol. 2009; 89: 319-325.
39. Singh N, Kumar L, Meena R, Velpandian T. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol. 2009; 65: 545-549.
40. Sohn SK, Oh SJ, Kim BS, et al. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leuk Lymphoma. 2011; 52: 1024-1029.
41. Takahashi N, Wakita H, Miura M, et al. Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronicphase chronic myeloid leukemia. Clin Pharmacol Ther. 2010; 88: 809-813.
42. Zhong JS, Meng FY, Xu D, et al. Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients. Acta Haematol. 2012; 127: 221-227.
43. Qb Li, Chen C, Zc Chen, et al. Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients. Acta Pharmacol Sin. 2010; 31: 999-1004.
44. Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res. 2009; 33: 271-275.
45. Faber E, Friedecký D, Mi-cová K, et al. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Ann Hematol. 2012; 91: 923-929.
46. Mahon FX, Molimard M. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia. Leuk Res. 2009; 33: 1147-1148; author reply 1149-1150.
47. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561-566.
48. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007; 25: 1107-1113.
49. Breccia M, Cannella L, Stefanizzi C, et al. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. Hematol Oncol. 2010; 28: 89-92.
50. Kobayashi S, Kimura F, Kobayashi A, et al. Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients. Ann Hematol. 2009; 88: 311-315.
51. Kimura O, Yamamoto O, Hisamitsu K, et al. Usefulness of low-dose and long-term administration of imatinib in patients with liver metastases of rectal GIST and GIST of stomach. Gan To Kagaku Ryoho. 2010; 37: 2285-2287.
52. Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia- positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood. 2009; 113: 4497-4504.
53. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn. 1993; 21: 735-750.
54. Wang Y, Chia YL, Nedelman J, et al. A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit. 2009; 31: 579-584.
55. Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 2011; 50: 551-603.
56. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. Philadelphia, PA: Lippincott Williams & Wilkins; 1995.
57. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005; 44: 879-894.
58. Haouala A, Widmer N, Guidi M, et al. Prediction of free imatinib concentrations based on total plasma levels in gist patients. Br J Clin Pharmacol. 2012 Aug 15 [Epub ahead of print].
59. Gibbons J, Egorin MJ, Ramanathan RK, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008; 26: 570-576.
60. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006; 165: 819-829.
61. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev. 2001; 33: 161-235.
62. Eechoute K, Fransson MN, Reyners AK, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res. 2012; 18: 5780-5787.
63. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009; 113: 5401-5411.
64. Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011; 35: 626-630.
65. Park SJ, Choi IK, Seo HY, et al. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. Acta Haematol. 2007; 118: 219-221.
66. Horikoshi A, Takei K, Sawada S. Effects of lower dose of imatinib to CML patients. Leuk Res. 2003; 27: 1167.
67. Horikoshi A, Takei K, Sawada S. Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML). Leuk Res. 2007; 31: 574-575.
68. Ohnishi K, Nakaseko C, Takeuchi J, et al. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci. 2012; 103: 1071-1078.
69. Ramanathan RK, Egorin MJ, Takimoto CHM, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008; 26: 563-569.
70. Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol. 2004; 53: 102-106.
71. Pursche S, Schleyer E, von Bonin M, et al. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol. 2008; 3: 198-203.
72. Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol. 2004; 54: 290-294.
73. van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res. 2007; 13: 7394-7400.
74. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry on population pharmacokinetics. Fed Regist. 1999; 64: 6663-6664.
75. Svensson E, van der Walt J-S, Barnes KI, et al. Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. Br J Clin Pharmacol. 2012; 74: 465-476.
76. Molimard M, Bouchet S., Poulette S., et al. Definition of an imatinib trough concentration threshold in the treatment of advancedgastrointestinal stromal tumors (GIST). J Clin Oncol. 2011 (suppl; abstr 10013).
77. Tanaka MF, Kantarjian H, Cortes J, et al. Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother. 2012; 13: 815-828.
78. Laneuville P, DiLea C, Yin OQP, et al. Comparative in vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia. J Clin Oncol. 2010; 28: e169-e171.
79. Soverini S, Rosti G, Iacobucci I, et al. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC50? Oncologist. 2011; 16: 868-876.
80. White D, Saunders V, Lyons AB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood. 2005; 106: 2520-2526.